SynthesisPloS one2023

Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.

Tingting Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.